Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295788 | 1.00 | HSD11B1 (0.33) | HSD11B1CYP1A2EPHX1MEN1ALDH1A1 | |
| SCHEMBL11665887 | 0.78 | HSD11B1 (0.34) | HSD11B1CYP1A2EPHX1TRPV1 | |
| SCHEMBL7978200 | 0.76 | HSD11B1 (0.33) | HSD11B1CYP1A2EPHX1TRPV1 | |
| SCHEMBL29112277 | 0.76 | HSD11B1 (0.33) | HSD11B1CYP1A2EPHX1TRPV1 | |
| SCHEMBL29682105 | 0.76 | HSD11B1 (0.33) | HSD11B1CYP1A2EPHX1TRPV1 | |
| SCHEMBL1784428 | 0.76 | HSD11B1 (0.31) | HSD11B1CYP1A2EPHX1 | |
| SCHEMBL20533656 | 0.75 | GRM2 (0.39) | HSD11B1EPHX1 | |
| SCHEMBL20533654 | 0.75 | GRM2 (0.39) | HSD11B1EPHX1 | |
| SCHEMBL20897002 | 0.74 | HSD11B1 (0.32) | HSD11B1CYP1A2EPHX1 | |
| SCHEMBL6036659 | 0.73 | TRPA1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377422-B2 | Carboxamide derivatives having cooling properties | GIVAUDAN S.A. (CH) | 2013-02-19 | — | — | US | disclosed |
| US-20110182833-A1 | Carboxamide Derivatives Having Cooling Properties | GIVAUDAN SA (CH) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182833-A1 | Carboxamide Derivatives Having Cooling Properties | CPS1, NQO2, NDUFA2 | HSD11B1 3432/4885CYP1A2 192/4885EPHX1 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.